Find clinical trials

In patients with previously untreated chronic lymphocytic leukemia (CLL). The duration of each cycle is 28 days. Arm A: sonrotoclax + zanubrutinib up to 15 cycles. Arm B: venetoclax plus acalabrutinib up to 14 cycles.

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

This is a phase 2/3, global, multicenter, randomised, double-blind, placebo-controlled, 3-arm study designed to assess the efficacy and safety of BHV-7000 in participants with refractory focal onset epilepsy who are stable with atleast 1 and upto 3 antiseizure medications. The goals of this study are to: . See how well BHV-7000 works to decrease the number of seizures the participant has in a month as compared to a placebo (tablet with no medication). . See if BHV-7000 is safe and tolerable.

This is a Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy and the goals of this study are to: • See if BHV-7000 is safe (assessing how many side effects you and others in this study have) and tolerable (how well you and others in this study tolerate any side effects) over 52 weeks. • See how well BHV-7000 works in reducing seizures; how often The study has 2 phases. • Long-term Treatment Phase: This phase will last for 52 weeks, and you will have 7 visits to the study site and will take the study drug every day. • Follow-up Phase: This phase will last for 2 weeks after your last dose of the study drug, and there will be 1 visit to the study site.